AIM: To observe the effect of octreotide on apoptosis rate of human pancreatic cancer cells PC-3 after transfected with somatostatin receptor type 2 (SST2) gene. METHODS: SST2 plasmid was transfected into PC-3 cells by liposome. Result of transfection was detected by immunocytochemical staining and Western blotting. Apoptosis rates of PC-3 cells under different dosages of octreotide were measured by MTT assay and flow cytometry (FCM). RESULTS: Apoptosis rate caused by octreotide of transfected PC-3 cells was 7.56+/-1.06% at the dosage of 0.20 microg/mL, 9.25+/-1.73% at the dosage of 0.40 microg/mL and 14.18+/-2.71% at the dosage of 0.80 microg/mL. Apoptosis rate caused by octreotide of non-transfected PC-3 cells was 5.76+/-0.75% at the dosage of 0.20 microg/mL, 6.69+/-0.80% at the dosage of 0.40 microg/mL and 7.26+/-1.28% at the dosage of 0.80 microg/mL. Transfected PC-3 cells growth inhibition rate caused by octreotide was 9.36+/-1.34% at the dosage of 0.20 microg/mL, 12.03+/-1.44% at the dosage of 0.40 microg/mL and 20.23+/-4.21% at the dosage of 0.80 microg/mL. Non-transfected PC-3 cells growth inhibition rate caused by octreotide was 6.44+/-0.66% at the dosage of 0.20 microg/mL, 7.65+/-0.88% at the dosage of 0.40 microg/mL and 9.29+/-1.32% at the dosage of 0.80 microg/mL. We found that octreotide caused higher apoptosis rate and inhibition rate in transfected groups than in non-transfected groups (P<0.05) at the tested dosages (0.20, 0.40 and 0.80 microg/mL). CONCLUSION: Deficiency of SST2 was probably the major reason why octreotide had little effect on PC-3 cells. Transfecting SST2 gene could strengthen the ability of octreotide of killing PC-3 cells. It provided an experimental evidence for using both octreotide and transfection with SST2 gene on clinical treatment of pancreatic cancer.
AIM: To observe the effect of octreotide on apoptosis rate of humanpancreatic cancer cells PC-3 after transfected with somatostatin receptor type 2 (SST2) gene. METHODS:SST2 plasmid was transfected into PC-3 cells by liposome. Result of transfection was detected by immunocytochemical staining and Western blotting. Apoptosis rates of PC-3 cells under different dosages of octreotide were measured by MTT assay and flow cytometry (FCM). RESULTS: Apoptosis rate caused by octreotide of transfected PC-3 cells was 7.56+/-1.06% at the dosage of 0.20 microg/mL, 9.25+/-1.73% at the dosage of 0.40 microg/mL and 14.18+/-2.71% at the dosage of 0.80 microg/mL. Apoptosis rate caused by octreotide of non-transfected PC-3 cells was 5.76+/-0.75% at the dosage of 0.20 microg/mL, 6.69+/-0.80% at the dosage of 0.40 microg/mL and 7.26+/-1.28% at the dosage of 0.80 microg/mL. Transfected PC-3 cells growth inhibition rate caused by octreotide was 9.36+/-1.34% at the dosage of 0.20 microg/mL, 12.03+/-1.44% at the dosage of 0.40 microg/mL and 20.23+/-4.21% at the dosage of 0.80 microg/mL. Non-transfected PC-3 cells growth inhibition rate caused by octreotide was 6.44+/-0.66% at the dosage of 0.20 microg/mL, 7.65+/-0.88% at the dosage of 0.40 microg/mL and 9.29+/-1.32% at the dosage of 0.80 microg/mL. We found that octreotide caused higher apoptosis rate and inhibition rate in transfected groups than in non-transfected groups (P<0.05) at the tested dosages (0.20, 0.40 and 0.80 microg/mL). CONCLUSION: Deficiency of SST2 was probably the major reason why octreotide had little effect on PC-3 cells. Transfecting SST2 gene could strengthen the ability of octreotide of killing PC-3 cells. It provided an experimental evidence for using both octreotide and transfection with SST2 gene on clinical treatment of pancreatic cancer.
Authors: N Delesque; L Buscail; J P Estève; N Saint-Laurent; C Müller; G Weckbecker; C Bruns; N Vaysse; C Susini Journal: Cancer Res Date: 1997-03-01 Impact factor: 12.701
Authors: L Buscail; N Saint-Laurent; E Chastre; J C Vaillant; C Gespach; G Capella; H Kalthoff; F Lluis; N Vaysse; C Susini Journal: Cancer Res Date: 1996-04-15 Impact factor: 12.701
Authors: D Hoyer; G I Bell; M Berelowitz; J Epelbaum; W Feniuk; P P Humphrey; A M O'Carroll; Y C Patel; A Schonbrunn; J E Taylor Journal: Trends Pharmacol Sci Date: 1995-03 Impact factor: 14.819
Authors: D Moneta; C Richichi; M Aliprandi; P Dournaud; P Dutar; J M Billard; A S Carlo; C Viollet; J P Hannon; D Fehlmann; C Nunn; D Hoyer; J Epelbaum; A Vezzani Journal: Eur J Neurosci Date: 2002-09 Impact factor: 3.386
Authors: Scott A Burchett; Paul Flanary; Christopher Aston; Lixin Jiang; Kathleen H Young; Peter Uetz; Stanley Fields; Henrik G Dohlman Journal: J Biol Chem Date: 2002-04-08 Impact factor: 5.157
Authors: Julie Guillermet; Nathalie Saint-Laurent; Philippe Rochaix; Olivier Cuvillier; Thierry Levade; Andrew V Schally; Lucien Pradayrol; Louis Buscail; Christiane Susini; Corinne Bousquet Journal: Proc Natl Acad Sci U S A Date: 2002-12-18 Impact factor: 11.205
Authors: M Raderer; G Hamilton; A Kurtaran; J Valencak; I Haberl; O Hoffmann; G V Kornek; F Vorbeck; M H Hejna; I Virgolini; W Scheithauer Journal: Br J Cancer Date: 1999-02 Impact factor: 7.640